• SGLT2 Inhibitors Could Be Cost Effective in Developing Countries

    12 days ago - By Medscape

    In low- to middle-income countries, SGLT2 inhibitors could reduce diabetes complications at lower but feasible prices; they are cost effective at current prices in people with heart or kidney disease.
    Medscape Medical News
    Read more ...